Mark Pearson

Mark Pearson has a diverse work experience in the pharmaceutical industry. Mark started their career at Novartis as a Laboratory Head from 2001 to 2007. Mark then joined AstraZeneca as an Associate Principle Scientist from 2007 to 2010. Currently, they are working at Boehringer Ingelheim, where they have held various roles since 2010. Mark started as a Director, leading a group of labs focused on target identification, target validation, and drug development in Oncology research, and also leading a global team focused on portfolio development of new biological entities. In 2014, they became the Vice President of Cancer Cell Signaling, and in 2022, they took on the role of Vice President of Cancer Pharmacology.

Mark Pearson attended Bristol Grammar School from 1981 to 1998. Mark then pursued a Bachelor's degree in Biochemistry at the University of Oxford from 1988 to 1992, where they also obtained a Master's degree from Corpus Christi College in the same field. Mark completed their education with a PhD in Cancer from The University of Manchester, graduating in 1996.